Komori
Zeria Pharmaceutical (4559) · PolicyRestated

Application of the Accounting Standard for Fair Value Measurement and Related Standards

First written in FY2022-Q1. 5 of 7 entries say "Restated". Latest entry: FY2023.

7entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2022-Q1 – FY20232021: 220212022: 320222023: 22023
Same theme, other companies
Preparations for the adoption of accounting standards for fair value measurementA theme 1882 companies write about · 5 as a headwind · 3 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 196 companies compared. The sentences above are computed from all 196.Comparing 200 of the theme's 1923 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2023RestatedAnnual report

    「From the beginning of the current consolidated fiscal year, the Company applied the Implementation Guidance on Accounting Standard for Fair Value Measurement (Accounting Standards Board of Japan Guidance No. 31, 17 June 2021) and decided to apply the new accounting policies prescribed by it prospectively. There was no impact on the consolidated financial statements for the current consolidated fiscal year.」

    The Fair Value Measurement Accounting Standard Implementation Guidance was applied from the beginning of the fiscal year, and the company states that there has been no impact on the financial statements.
  2. FY2023-Q3RestatedAnnual report

    「From the beginning of the first quarter, the Company applied the Implementation Guidance on Accounting Standard for Fair Value Measurement (Accounting Standards Board of Japan Guidance No. 31, 17 June 2021; hereinafter, the Fair Value Measurement Implementation Guidance) and, in accordance with the transitional treatment prescribed in Paragraph 27-2 of the guidance, decided to apply the new accounting policies prescribed by it prospectively. There was no impact on the quarterly consolidated financial statements for the current third quarter.」

    The Group continues to explain the application of the Fair Value Measurement Guidance and that there was no impact on the quarterly consolidated financial statements.
  3. FY2023-Q2RestatedAnnual report

    「From the beginning of the first quarter, the Company applied the Implementation Guidance on Accounting Standard for Fair Value Measurement (Accounting Standards Board of Japan Guidance No. 31, 17 June 2021; hereinafter, the Fair Value Measurement Implementation Guidance) and, in accordance with the transitional treatment prescribed in Paragraph 27-2 of the guidance, decided to apply the new accounting policies prescribed by it prospectively. There was no impact on the quarterly consolidated financial statements for the current second quarter.」

    The company continues to state that applying the implementation guidance on the accounting standards for fair value measurement has had no impact on the financial statements.
  4. FY2023-Q1Additional adoption of the implementation guidance for the fair-value measurement accounting standardAnnual report

    「From the beginning of the current first quarter, the Company applied the Implementation Guidance on Accounting Standard for Fair Value Measurement (Accounting Standards Board of Japan Guidance No. 31, 17 June 2021; hereinafter, the Fair Value Measurement Implementation Guidance) and, in accordance with the transitional treatment prescribed in Paragraph 27-2 of the guidance, decided to apply the new accounting policies prescribed by it prospectively. There was no impact on the quarterly consolidated financial statements for the current first quarter.」

    In addition to the existing fair value measurement standards, the Company applied the implementation guidance from the beginning of the current quarter and applied the new accounting policies prospectively. It stated that there was no impact on the financial statements.
  5. FY2022-Q3RestatedAnnual report

    「From the beginning of the first quarter, the Company applied the Accounting Standard for Fair Value Measurement (Accounting Standards Board of Japan Statement No. 30, 4 July 2019; hereinafter, the Fair Value Measurement Standard) and related standards. In accordance with the transitional treatment prescribed in Paragraph 19 of the Fair Value Measurement Standard and Paragraph 44-2 of the Accounting Standard for Financial Instruments (Accounting Standards Board of Japan Statement No. 10, 4 July 2019), the Company decided to apply the new accounting policies prescribed by the Fair Value Measurement Standard and related standards prospectively. There was no impact on the quarterly consolidated financial statements for the current third quarter.」

    The Company continues to disclose the application of the fair value measurement standards and the prospective application of the new accounting policies, stating that there was no impact on the quarterly financial statements.
  6. FY2022-Q2RestatedAnnual report

    「From the beginning of the first quarter, the Company applied the Accounting Standard for Fair Value Measurement (Accounting Standards Board of Japan Statement No. 30, 4 July 2019; hereinafter, the Fair Value Measurement Standard) and related standards. In accordance with the transitional treatment prescribed in Paragraph 19 of the Fair Value Measurement Standard and Paragraph 44-2 of the Accounting Standard for Financial Instruments (Accounting Standards Board of Japan Statement No. 10, 4 July 2019), the Company decided to apply the new accounting policies prescribed by the Fair Value Measurement Standard and related standards prospectively. There was no impact on the quarterly consolidated financial statements for the current second quarter.」

    The Company continues to disclose the application of the fair value measurement standards and the prospective application of the new accounting policies, stating that there was no impact on the quarterly financial statements.
  7. FY2022-Q1First statedAnnual report

    「From the beginning of the current first quarter, the Company applied the Accounting Standard for Fair Value Measurement (Accounting Standards Board of Japan Statement No. 30, 4 July 2019) and related standards, and decided to apply the new accounting policies prescribed by those standards prospectively. There was no impact on the quarterly consolidated financial statements for the current first quarter.」

    From 1 April 2021, the Company applied the accounting standards for fair value measurement and related standards and applied the new accounting policies prospectively. It stated that there was no impact on the quarterly financial statements.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Zeria Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Application of the Accounting Standard for Fair Value Measurement and Related Standards | ZERIA PHARMACEUTICAL CO.,LTD. (4559) | Komori